Healthy volunteers help Fine-Tune Long-Acting HIV prevention drug
NCT ID NCT06033547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two different long-acting versions of the HIV drug cabotegravir in 56 healthy adults. The goal was to see how safe they are and how the body processes them. No treatment was given for HIV; the study simply gathered information to help develop better formulations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Austin, Texas, 78744, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men
- A pharmacist's touch: could structured medication reviews boost HIV treatment success?
- A new Fast-Track HIV care model aims to Re-Engage those lost to care
- Can a smartphone app curb HIV risk in south Korea's young gay men?